Anthracycline-based Regimens Superior in Treating High-Risk, HER2-negative Breast CancerDebra Hughes, MS
Anthracycline-based regimens have proven to be one of the most effective treatments in this setting. As certain cytotoxic antineoplastic agents, such as anthracyclines, generate reactive oxygen species as a by-product of their mechanism of action, we examined whether redox protein expression was ...
Trastuzumab improves survival in the adjuvant treatment of HER-positive breast cancer, although combined therapy with anthracycline-based regimens has been... A Buzdar,N Ibrahim,D Francis,... 被引量: 1233发表: 2005年 Pathologic Complete Response After Neoadjuvant Chemotherapy Plus Trastuzumab Predicts...
Clearly, there are arguments in favour of considering early aggressive rituximab and chemotherapy regimens in patients with FL requiring treatment, and it is hoped that new prognostic tools will help us to more accurately identify which patients are most likely to benefit....
Efficacy of neoadjuvant therapy with trastuzumab concurrent with anthracycline- and nonanthracycline-based regimens for HER2-positive breast cancer 来自 EBSCO 喜欢 0 阅读量: 14 摘要: BACKGROUND:The aim of this study was to evaluate the pathologic complete response (pCR) rates and relapse-free ...
Anthracycline-containing regimens, namely cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) or CHOEP (CHOP + etoposide), represent the current standard of care for patients with newly diagnosed peripheral T-cell lymphomas (PTCLs), although responses are unsatisfactory. In this study,...
The median overall survival time after t-MN was 10 months.t-MN is a relatively infrequent, long-term, and severe complication after first-line treatment for APL with ATRA and anthracycline-based regimens. Therapeutic strategies to reduce the incidence of t-MN are warranted. 展开 ...
Phase II neoadjuvant trial of Albumin-Bound Paclitaxel, Trastuzumab and Pertuzumab followed by anthracycline based regimens in patients with operable Her2 positive breast cancer (OMC-BC05)doi:10.1016/S0960-9776(21)00174-0M. IwamotoA. Matsutani...
The present study investigated the survival benefit of non–anthracycline (ANT)-based vs ANT-based regimens in a large-scale, real-world cohort of patients with extranodal natural killer (NK)/T-cell lymphoma, nasal type (ENKTCL). Within the China Lymphoma Collaborative Group (CLCG) database (...
Abstract 6430: Redefining therapy regimens for triple negative breast cancer - Exploiting the epigenetic effects of eribulin action When patients present with advanced or metastatic disease, or upon relapse following treatment with an anthracycline or a taxane, eribulin is administered as... M Bagheri,...